AYTU BIOPHARMA, INC. — Cash Flow Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Capital Allocation
How management deploys cash: investing in the business (Capex + M&A) vs returning to shareholders (Buybacks + Dividends).
Capital Allocation Waterfall
Buybacks vs Stock-Based Comp
Net Debt Issuance
Cash Flow
Cash Flow by Activity
Operating Cash Flow↑+26.5% +$770K
$4M
Free Cash Flow↑+26.2% +$759K
$4M
Investing Cash Flow↓-100.0% -$381K
$0
Financing Cash Flow↑+152.0% +$1M
$2M
Capex↑+183.3% +$11K
$17K
Stock-Based Comp↑+87.4% +$132K
$283K
Debt Issued↓-90.2% -$11M
$1M
Debt Repaid↑+0.0% +$0
$465K
D&A↑+0.0% +$0
$100K
SBC Allocated Expense↑+87.4% +$132K
$283K
SBC Unrecognized Cost
—